Trump speeds review of psychedelics after Joe Rogan texted him about ibogaine. ‘Sounds great. Do you want FDA approval? Let’s do it’
- Posted on April 18, 2026
- By Fortune
- 0 Views
- 1 min read
In brief
The Trump administration is accelerating the regulatory process for psychedelic substances to advance medical research and therapeutic applications. Following informal discussions about natural compounds like ibogaine, officials are prioritizing FDA approval pathways for treating severe mental health conditions. This policy shift signals a significant change in how the government approaches controlled substances, focusing on their potential clinical benefits rather than recreational risks.
Trump speeds review of psychedelics after Joe Rogan texted him about ibogaine. ‘Sounds great. Do you want FDA approval? Let’s do it’
The administration is taking steps to ease restrictions and spur research on using the drugs for medical purposes, including conditions like severe depression.
